Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization ... ( LA JOLLA Calif. May 14 /- Duska T...)

HOME >> MEDICINE >> NEWS

Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals

Date:5/14/2008

LA JOLLA, Calif., May 14 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that scientists from the University of Pennsylvania's Center for Research on Reproduction and Women's Health have published the results of the Company's sponsored study showing that extracellular ATP (adenosine 5'-triphosphate) improves sperm motility and increases fertilizing capability in mice.

The data was published online in the journal Biology of Reproduction (http://www.biolreprod.org/cgi/content/abstract/biolreprod.107.065565).

The University of Pennsylvania scientists studied sperm obtained from two mouse strains: one with normal and the other one with low fertilization capacity. Extracellular ATP treatment of these sperm in vitro (outside of the body) resulted in improved sperm motility parameters and was associated with a rapid increase in the level of intracellular calcium. The effect was inhibited by two P2 receptor antagonists. Furthermore, extracellular ATP treatment of mouse sperm resulted in increased success rates of in vitro fertilization (IVF) procedures. The improved fertilization rate was much more pronounced when sperm from the mouse strain with low fertility were used.

The authors suggest that ATP's activation of P2 receptors to modulate sperm function may be beneficial for artificial reproductive techniques.

"We are extremely pleased with the positive results of sperm treatment with ATP, which were obtained in this second Duska-sponsored study," said Dr. Amir Pelleg, Duska's President and Chief Scientific Officer. "These results indicate that the mechanism of action of extracellular ATP on improving sperm motility and fertilization potency is mediated by P2 receptors and increased level of intracellular calcium. The data further support the development of ATPotent(TM
'/>"/>

SOURCE Duska Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
2. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2008 Financial Results on Wednesday, May 14, 2008 at 4:30 P.M. EST
3. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
4. Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics
5. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
6. Nektar Therapeutics Announces First Quarter 2008 Results
7. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
8. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
9. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
10. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
11. Precision Therapeutics Adds 8 Million Covered Lives Under Contract

Post Your Comments:

(Date:12/1/2009)...Could identify those who would benefit from liver ...UESDAY, Dec. 1 (HealthDay News) -- A CT scan of li...er may help predict overall survival after chemoth... (Avastin) to cytotoxic chemotherapy has been show...colorectal cancer and to produce better results in...

(Date:12/1/2009)... , MIAMI, FL (December 1, 2009)The Clinical Resea...ler School of Medicine, has been honored for its s... the LEED designation, established by the U.S. Gre...ding Certification Institute (GBCI). LEED is the n...ction and operation of green buildings., "Having ...

(Date:12/1/2009)..., , SMITHFIELD, R.I., Dec...ective equipment, bad assumptions are hazardous an...5 years of government regulation, a handful of per...ing both the effectiveness of occupational Hearin...ing. ,, A new free, white paper from Howard Le...

(Date:12/1/2009)..., , WASHINGTON, Dec. 1 /PRNewswire-USNewswi... Agency for International Development: ,, Chair...e Committee. ,, I am honored to be nominated by...United States Agency for International Development...e Agency. ,, Secretary of State Clinton has ex...

(Date:12/1/2009)... Barcelona, 30 November 2009. Performing surgica...e a chimera and has become a reality. This is demo...g NOTES (Natural Orifice Transluminal Endoscopy Su...s surgical access using the body,s natural orifice...t: lack of scars, shorter hospital stay and faster...

[0] CT Scan May Predict Colon Cancer Survival [0] UM Clinical Research Building awarded prestigious LEED Building Certification [0] New White Paper Details Six Common Bad Assumptions About Hearing Protection [0] Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 [0] Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus

... Ethnic rhinoplasty will be discusse...American Society for Aesthetic Plastic Surgery (AS...nvention Center May 2-7, 2009. , ...both their individuality and ethnic identity. But...

... Non-surgical facial rejuvenation te...he Annual Meeting of the American Society for Aest...andalay Bay Hotel & Convention Center May 2-7,... can erase wrinkles, tighten the skin, and improve...

... Nashville hair transplant center, P...sed on expanding their serviceable region. PAI Nas...phis, Knoxville, Clarksville, Chattanooga, Birming...spread throughout Tennessee, Kentucky, and Alabama...

... As citizens search to protect thems...otections may actually be right under our nose. Br...ing this crisis , New Por...itizens are mobilizing to protect themselves by we...

...ed $750,000 by Avon Foundation for Breast Cancer A...nne Mandelblatt, MD, MPH, and Harriet Weiner have ...ion to walk to raise funds and awareness of breast... Lombardi. , , The team has been training since ...

...H1N1 strain lacks "virulent characteristics" of de...ay 2 (HealthDay News) -- The scope of the swine fl... thought, test results released Friday in Mexico s... people have died. , Mexico had reported about 2,5...

Ethnic Rhinoplasty: The "Classic" Nose Job is Not One Size Fits All Saving Face...No Need For A Knife! Hair Transplant Office Expands Serviceable Area Cleanose Personal Air Filters Offer Added Protection From Inhaled Viruses/ Swine Flu/ H1N1 and Other Inhaled Dangers Georgetown's Lombardi Comprehensive Cancer Center and the Capital Breast Care Center Pound the Pavement to Save Lives Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought

(Date:12/1/2009)... Dec. 1 CCS Medical, Inc. a leadin... today announced that it has received approval fro...of Delaware (the "Court") for its bidding procedur...ale of substantially all of its assets. ,, Purs...t approved bidding procedures for the sale of subs...

(Date:12/1/2009)... 1 CEL-SCI Corporation (...nd a developer of vaccines and therapeutics for th... announced today that it has retained the services...n (CRO) to run CEL-SCI,s upcoming Phase III clinic...with the Company,s lead product candidate, Multiki...

(Date:12/1/2009)... Dec. 1 MedQuist Inc. ...-enabled clinical documentation services, today an...dial Design, Inc. has been integrated with SpeechQ...cognition system. The solution is being demonstrat...SNA) convention November 29 through December 2. ...

Breaking Medicine Technology:CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3 MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 1 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 1 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 3 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 4 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 1 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 2 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 3 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 4

[0] CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures [0] CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine [0] MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology

...-Company to Host Conference Call at 9:00 a.m. EDT-... Corp. (Nasdaq: MEMY ) today announced top-line d...d, placebo-controlled Phase 2a study,of MEM 1003, ...zheimer,s,disease. The trial enrolled 183 subjects... 40 centers in the United States and included mono...

...ORLANDO, Fla., Oct. 13 Acutely ill, hospitalized,...rovement in symptoms,after taking INVEGA(TM) (pali...SEROQUEL(R)(a) (quetiapine) and placebo. Symptom i...ve days into therapy and continued,through the end...inary data,presented today at the 20th Annual U.S....

Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...

Medicine Products:

Antifungal Serum Level, Itraconazole Antidiuretic Hormone, Plasma Antidepressant Panel Anticochlear

Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization ...( LA JOLLA Calif. May 14 /- Duska T...),Health